[Effect of alpha dihydroergocryptine in patients with fibrocystic breast disease].

Abstract

OBJECTIVE:

To evaluate the effectiveness of alpha dihidroergocriptine in patients with fibrocystic mastopathy.

PATIENTS AND METHODS:

Patients with diagnosis of fibrocystic breast disease were included in a prospective longitudinal blind double, controlled with placebo study. Patients were randomly assigned to one of two treatment groups: of treatment group A: Alpha dihidroergocriptine tablets of 10 mg, group B: Placebo, during 6 months. After to basal evaluation, the patients were revised in a monthly way evaluating the following symptoms and signs: mastalgia, mammary tension, presence of nodules, nipple secretion, and the presence of adverse events.

RESULTS:

39 patients with alpha dihidroergocriptine and 38 with placebo. Mastodinia, a satisfactory response was observed in 100% of alpha dihidroergocriptine group vs 61.11% of placebo group (p = 0.0002). Mastalgia responded in 100% of alpha dihidroergocriptine group vs 64.86% of placebo group (p = 0.0003). Galactorrea responded 100% of alpha dihidroergocriptine group vs 93.33% of the placebo. The nodules in the group alpha dihidroergocriptine disappeared in 23.1% and in 21.1% of the placebo group. Ultrasound evaluation of the nodules did not show significant differences between both groups. Prolactin levels showed a decrease in the group treated with alpha dihidroergocriptine with an important difference between both groups at the end of the 6 months study period. There were not differences in the presence of adverse events between groups.

CONCLUSIONS:

Alpha dihidroergocriptine is effective in the treatment of fribrocystic breast disease with minimum adverse events when compared with similar drugs.

• Authors: Eugenio Castillo, Miguel Garibay, Felio Mirabent
• Journal: Ginecologia y obstetricia de Mexico (Ginecol Obstet Mex) Vol. 74 Issue 11 Pg. 580-4 (Nov 2006) ISSN: 0300-9041 [Print] Mexico
• Vernacular Title: Efecto del alfa dihidroergocriptina en pacientes con mastopatía fibroquística.
• PMID: 17357577 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Dihydroergocryptine

Topics

• Adult
• Dihydroergocryptine (therapeutic use)
• Double-Blind Method
• Female
• Fibrocystic Breast Disease (drug therapy)
• Humans
• Middle Aged
• Prospective Studies